GSK Wants USPTO Appeals Board Ruling Overturned

Law360, New York (September 16, 2008, 12:00 AM EDT) -- The U.S. Board of Patent Appeals and Interferences has erroneously invalidated claims for several inhaler patents in favor of Novartis Corp., according to a complaint filed by Glaxo Group Ltd. and SmithKline Beecham Corp.

GSK lodged the suit on Friday in the U.S. District Court for the District of Columbia, asking the court to overturn decisions made by the U.S. Patent and Trademark Office's appeals and interferences board during a July interference proceeding between the pharmaceutical giants.

According to the complaint, the interference board initiated the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.